德国生物技术公司BioNTech周二公布第三季度净利润1.845亿欧元（2.065亿美元），扭转去年同期的亏损，并上调2026年营收预测的下限。该公司去年同期同一季度净亏损为2870万欧元。
German biotechnology company BioNTech reported a third-quarter net profit of €184.5 million ($206.5 million) on Tuesday, reversing a year-earlier loss, and raised the lower end of its 2026 revenue forecast. The company posted a net loss of €28.7 million in the same quarter last year.
BioNTech现在预计全年营收为17亿欧元至19亿欧元，提升了此前预测的下限，从16亿欧元上调。
BioNTech now expects full-year revenue of €1.7 billion to €1.9 billion, raising the lower end of its previous forecast from €1.6 billion.
七至九月期间营收同比下降15.1%，至12.9亿欧元，全球对COVID-19疫苗的需求持续减弱。较低的法律费用帮助公司实现盈利。
Revenue declined 15.1% year-on-year to €1.29 billion in the July-September period as global demand for COVID-19 vaccines continued to weaken. Lower legal expenses helped the company return to profitability.
其他经营费用从去年同期的7.295亿欧元降至1.636亿欧元，当年BioNTech计提了与法律纠纷相关的重大一次性费用。
Other operating expenses fell to €163.6 million from €729.5 million a year earlier, when BioNTech recorded substantial one-time charges related to legal disputes.
公司报告每股稀释收益为0.73欧元，去年同期每股亏损为0.12欧元。
The company reported diluted earnings of €0.73 per share, compared with a loss of €0.12 per share in the same period last year.
经营利润达到1.25亿欧元，扭转了去年同期的4690万欧元经营亏损。
Operating profit reached €125 million, reversing an operating loss of €46.9 million a year earlier.
研发支出上升 BioNTech将研发支出提高32.5%，至7.481亿欧元，以推进癌症治疗的临床试验。
Research spending rises as BioNTech expands cancer drug development BioNTech increased research and development spending by 32.5% to €748.1 million as it advanced clinical trials for cancer treatments.
公司计划到2030年将多款肿瘤产品推向市场，以减少对COVID-19疫苗的依赖。
The company aims to bring several oncology products to market by 2030 as it seeks to reduce its reliance on COVID-19 vaccines.
尽管实现了季度盈利，BioNTech报告2026年前九个月净亏损扩大。
Despite returning to quarterly profitability, BioNTech reported a wider net loss for the first nine months of 2026.
该公司净亏损从去年同期的8.311亿欧元增至11.7亿欧元。九个月期间营收从19.6亿欧元降至15.1亿欧元。
The company's net loss increased to €1.17 billion from €831.1 million in the same period last year. Revenue for the nine-month period declined to €1.51 billion from €1.96 billion.